Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.98 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.98 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 3/20 | 0.86 |
| ▸ | FABP3 | P05413 | 1/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.64 |
| ▸ | PTAFR | P25105 | 1/20 | 0.64 |
| ▸ | HTR1D | P28221 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.64 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.61 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | GMNN | O75496 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231824 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL2036043 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL244839 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL24563 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL22693933 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL10498112 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL236969 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL37475 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL233046 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL234790 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| US-12576037-B2 | Polymer-encapsulated drug particles | TONIC MEDICAL, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4106828-B1 | POLYMER-ENCAPSULATED DRUG PARTICLES | TONIC MEDICAL INC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4678198-A2 | POLYMER-ENCAPSULATED DRUG PARTICLES | Tonic Medical, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| US-12440839-B2 | High-throughput system and method for the temporary permeabilization of cells using lipid bilayers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-14 | — | — | US | claimed |
| EP-4626400-A1 | NOVEL POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME | Generation Bio Co. (US) | 2025-10-08 | — | — | EP | claimed |
| EP-4610652-A1 | YAXAB NANOPORE, NANOPORE SYSTEM COMPRISING SAME AND APPLICATIONS THEREOF | Korea Research Institute of Bioscience and Biotechnology (KR) | 2025-09-03 | — | — | EP | claimed |
| WO-2025090663-A1 | NOVEL POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME | GENERATION BIO CO. (US) | 2025-05-01 | — | — | WO | claimed |
| WO-2025019468-A1 | LIPID NANOPARTICLES AND USES THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-01-23 | — | — | WO | claimed |
| US-20180251752-A1 | PHOSPHOLIPID NANOGEL FOR ENZYME STABILIZATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-06 | — | — | US | claimed |
| US-20170333348-A1 | MASS PRODUCTION AND SIZE CONTROL OF NANOPARTICLES THROUGH CONTROLLED MICROVORTICES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2017-11-23 | — | — | US | claimed |
| US-20150182461-A1 | Mass Production and Size Control of Nanoparticles Through Controlled Microvortices | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2015-07-02 | — | — | US | claimed |
| WO-2013192310-A1 | MASS PRODUCTION AND SIZE CONTROL OF NANOPARTICLES THROUGH CONTROLLED MICROVORTICES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-12-27 | — | — | WO | claimed |
| US-8293339-B2 | Droplet bilayers | SRI INTERNATIONAL, INC. (US) | 2012-10-23 | — | — | US | claimed |
| EP-0730860-B1 | Mixed micelles | HOFFMANN LA ROCHE (CH) | 2002-01-02 | — | — | EP | claimed |
| US-5747066-A | PHOSPHATIDES, BILE ACID SALT OR DIHEXANOYLLECITHIN | HOFFMANN-LA ROCHE INC. (US) | 1998-05-05 | — | — | US | claimed |
| EP-0730860-A2 | Mixed micelles | F. HOFFMANN-LA ROCHE AG (CH) | 1996-09-11 | — | — | EP | claimed |
| EP-0011745-B1 | COLLOIDAL AQUEOUS FORMULATION FOR PHARMACY AND ITS PREPARATION | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-12-30 | — | — | EP | claimed |
| EP-0011745-A1 | Colloidal aqueous formulation for pharmacy and its preparation | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-06-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576037-B2 | Polymer-encapsulated drug particles | PHOSPHO1, SGMS1, SGMS2 | SMN1; SMN2 578/4885NR5A2 3443/4885NR5A1 3606/4885 |
| US-20150182461-A1 | Mass Production and Size Control of Nanoparticles Through Controlled Microvortices | PHOSPHO1, VCL, LIPG | SMN1; SMN2 2027/4885NR5A2 3774/4885NR5A1 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.